UID:
edocfu_9960074207802883
Format:
1 online resource (296 pages)
ISBN:
0-12-821456-2
Series Statement:
Woodhead Publishing Series in Biomaterials
Content:
"Biomaterials have existed for millennia as mechanical replacement structures following disease or injury. Biomaterial design has changed markedly from structural support with an "inert" immune profile as the primary objective to designs that elicit an integrative local tissue response and a pro-repair immune cell phenotype. Immunomodulatory Biomaterials: Regulating the Immune Response with Biomaterials to Affect Clinical Outcome offers a single, comprehensive reference on biomaterials for modulation of the host response, for materials scientists, tissue engineers and those working in regenerative medicine. This book details methods, materials and strategies designed to regulate the host immune response following surgical implantation and thus facilitate specific local cell infiltration and tissue deposition. There has been a dramatic transformation in our understanding of the role of the immune system, both innate and adaptive; these changes include recognition of the plasticity of immune cells, especially macrophages, cross-talk between the immune system and stem cells, and the necessity for in situ transition between inflammatory and regulatory immune cell phenotypes. The exploitation of these findings and the design and manufacture of new biomaterials is occurring at an astounding pace. There is currently no book directed at the interdisciplinary principles guiding the design, manufacture, testing, and clinical translation of biomaterials that proactively regulate the host tissue immune response. The challenge for academia, industry, and regulatory agencies to encourage innovation while assuring safety and maximizing efficacy has never been greater. Given the highly interdisciplinary requirements for the design, manufacture and use of immunomodulatory biomaterials, this book will prove a useful single resource across disciplines."
Note:
Includes index.
,
Intro -- Immunomodulatory Biomaterials: Regulating the Immune Response with Biomaterials to Affect Clinical Outcome -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Engineering physical biomaterial properties to manipulate macrophage phenotype: From bench to bedside -- 1.1. Introduction -- 1.2. Role of macrophages in tissue repair and the foreign body response -- 1.3. Modulation of macrophage function via physical biomaterial properties in vitro -- 1.3.1. Stiffness -- 1.3.2. Topography or 3D architecture -- 1.3.3. Ligand presentation or geometry of adhesion -- 1.4. Macrophage response to implanted biomaterials in vivo -- 1.4.1. Non-degradable biomaterials -- 1.4.2. Degradable biomaterials -- 1.5. Clinical insight into the effect of physical biomaterial properties on macrophages during tissue repair -- 1.5.1. Dental implants -- 1.5.2. Wound dressings -- 1.5.3. Materials for cardiovascular repair -- 1.6. Conclusions and future directions -- References -- Chapter 2: Early factors in the immune response to biomaterials -- 2.1. Introduction -- 2.2. Protein adsorption -- 2.2.1. Complement cascade -- 2.2.2. Coagulation -- 2.2.3. Immunoglobulins -- 2.2.4. Innate immunity -- 2.2.4.1. Neutrophils -- 2.2.4.2. Mast cells -- 2.2.4.3. Macrophages/monocytes -- 2.2.5. Adaptive immunity -- 2.2.5.1. Dendritic cells -- 2.2.5.2. T Cells -- 2.2.5.3. B Cells -- 2.3. Foreign body giant cells -- 2.4. Fibrous capsule -- 2.5. Signaling pathways activated -- 2.5.1. TLRs and MyD88-dependent signaling -- 2.5.2. Inflammasome activation -- 2.5.3. JAK/STAT pathway -- 2.6. Conclusion -- References -- Chapter 3: Nanotechnology and biomaterials for immune modulation and monitoring -- 3.1. Introduction -- 3.2. Autoimmunity -- 3.3. Allergy -- 3.4. Transplant rejection -- 3.5. Clinical trials of tolerogenic nanotherapies -- 3.5.1. Liposomal.
,
3.5.2. Virus-like particles -- 3.5.3. Metallic -- 3.5.4. Polymeric -- 3.6. Precision diagnostics -- 3.6.1. Liquid biopsy -- 3.6.2. Immunological niches -- 3.7. Outlook and conclusion -- Acknowledgments -- References -- Chapter 4: Immune-instructive materials and surfaces for medical applications -- 4.1. Introduction -- 4.1.1. Immune cells involved in inflammation -- 4.1.2. The foreign body response -- 4.2. Naturally occurring biomaterials with immune modulatory properties and their application in wound healing and reduct ... -- 4.3. Bioinstructive synthetic materials and their application in regenerative medicine -- 4.4. Developing ``immune-instructive´´ biomaterials -- 4.5. Concluding remarks -- References -- Chapter 5: Electrospun tissue regeneration biomaterials for immunomodulation -- 5.1. Introduction -- 5.2. Acknowledging immunomodulation in tissue engineering -- 5.3. Well-studied areas -- 5.3.1. Monocytes and macrophages -- 5.3.2. Platelets -- 5.4. Areas gaining attention -- 5.4.1. Neutrophils -- 5.4.2. Mast cells -- 5.5. Areas needing attention -- 5.5.1. Dendritic cells -- 5.5.2. Eosinophils -- 5.5.3. Basophils -- 5.5.4. Natural killer cells -- 5.5.5. T cells -- 5.5.6. B cells -- 5.6. Future directions -- 5.7. Conclusion -- References -- Chapter 6: Biomaterials and immunomodulation for spinal cord repair -- 6.1. Spinal cord injury -- 6.1.1. Acute phase of SCI -- 6.1.2. Subacute phase of SCI -- 6.1.3. Chronic phase of SCI -- 6.1.4. Self-repair after SCI -- 6.1.5. Translational potential of animal models of SCI -- 6.2. Immune response after SCI -- 6.3. Immunomodulation after spinal cord injury -- 6.4. Biomaterials for spinal cord repair -- 6.5. Immunomodulatory biomaterials for spinal cord injury -- 6.5.1. Immunomodulation by surface chemistry -- 6.5.2. Immunomodulation by topography -- 6.5.3. Immunomodulation by delivering agents.
,
6.5.3.1. Immunomodulation by providing biological ligands -- 6.5.3.2. Immunomodulation by delivering drugs -- 6.5.3.3. Immunomodulation by carrying cells -- 6.6. Natural immunomodulatory materials for spinal cord injury -- 6.7. Considerations and future directions -- 6.8. Conclusions and summary -- Acknowledgments -- References -- Chapter 7: Biomaterial strategies to treat autoimmunity and unwanted immune responses to drugs and transplanted tissu -- 7.1. Introduction -- 7.1.1. Burden of disease -- 7.1.2. Current treatment options and challenges -- 7.1.3. Immunological causes of aberrant immune responses -- 7.1.3.1. Immunological basis for autoimmune diseases -- 7.1.3.2. Immunological basis for transplant rejection, anti-drug antibodies, and allergies -- 7.1.4. Antigen-specific tolerance as a treatment goal -- 7.2. Scope -- 7.3. Biomaterials in development for autoimmunity and anti-drug antibodies -- 7.3.1. Lessons from trials of free peptide and free protein -- 7.3.1.1. Type 1 diabetes -- 7.3.1.2. Multiple sclerosis -- 7.3.2. Antigen delivery vehicles without additional regulatory cues -- 7.3.2.1. Antigen depots -- 7.3.2.2. Nanoparticles -- 7.3.2.3. Alternative nanoparticle vehicles -- 7.3.2.4. Targeting liver APCs -- 7.3.2.5. Targeting splenic APCs -- 7.3.3. Antigen delivery vehicles with additional regulatory cues -- 7.3.3.1. Small molecule immunomodulators -- 7.3.3.2. Cytokines -- 7.3.4. Peptide-MHC complexes -- 7.3.4.1. Soluble pMHC complexes -- 7.3.4.2. Multimeric pMHC complexes -- 7.3.4.3. Nanoparticle pMHC complexes -- 7.4. Biomaterials in development for transplant tolerance -- 7.4.1. Transplant ECDI-treated cells -- 7.4.2. PLGA scaffold with transplanted cells and additional immunomodulatory drugs -- 7.5. Future of the field -- 7.5.1. Challenges and future directions -- 7.5.1.1. Standardization of immunological goals and readouts.
,
7.5.1.2. Further improvement in nanoparticle design -- 7.5.1.3. Manufacturability -- 7.5.2. Current or upcoming clinical trials -- References -- Chapter 8: Lipids as regulators of inflammation and tissue regeneration -- 8.1. Introduction -- 8.2. LC-MS based approaches to analyze lipids and their oxidation products -- 8.3. Free PUFA and their oxidation products as signals for immunomodulation and tissue regeneration -- 8.4. Oxidized phospholipids as modulators of the inflammatory response -- 8.5. Phospholipid signatures of EV -- 8.6. Hydrolysis of MBV derived oxygenated lipids and their possible role in inflammation and tissue regeneration -- References -- Chapter 9: Biomaterials modulation of the tumor immune environment for cancer immunotherapy -- 9.1. Introduction -- 9.2. Fundamentals of cancer immunology and immunotherapy -- 9.2.1. Cancer biology: Setting the stage -- 9.2.2. The role of immunity in cancer -- 9.3. Immunomodulatory biomaterials in cancer therapy -- 9.3.1. Cancer immunotherapy -- 9.3.2. Immunomodulatory biomaterials -- 9.3.3. Direct interactions between cancer and the biomaterial immune microenvironment -- 9.3.4. Biomaterial scaffold cancer vaccines -- 9.3.5. Biomaterial scaffolds for cell-based cancer immunotherapy -- 9.3.6. Immune tissue engineering -- 9.4. Summary -- References -- Chapter 10: Circumventing immune rejection and foreign body response to therapeutics of type 1 diabetes -- 10.1. Introduction -- 10.1.1. Type 1 diabetes (T1D) -- 10.1.2. Insulin and other injectable therapeutics -- 10.1.3. Biomaterials/devices -- 10.1.4. CGMs and insulin pumps -- 10.1.5. Cellular therapies -- 10.1.6. Protective immunity -- 10.2. Immune rejection for cells/grafts -- 10.2.1. General concepts for graft implementation -- 10.2.2. Transplant procedures -- 10.2.3. Human donor considerations -- 10.2.4. Alternative cell sources.
,
10.2.4.1. Xenogeneic grafts -- 10.2.4.2. Allogeneic grafts -- 10.2.4.3. Syngeneic grafts -- 10.2.4.4. Autologous grafts -- 10.3. Biological hurdles to preventing graft rejection -- 10.4. Advances in eliminating rejection of non-encapsulated grafts -- 10.4.1. Edmonton protocol and anti-inflammatory strategies -- 10.4.2. Delivery of antigen/nucleotide-based drugs for rejection suppression -- 10.4.3. Engineering therapeutic cells to modulate immune response -- 10.4.4. Tolerogenic vaccines -- 10.4.5. Artificial antigen-presenting cells for inducing tolerance -- 10.5. Advances in preventing FBR to bulk encapsulation systems -- 10.5.1. Bioresorption vs. lack of biodegradability -- 10.5.2. Non-biodegradable hydrogels/alginate and stable immune isolation -- 10.5.3. Effects of altering physical architecture -- 10.5.3.1. Size and shape -- 10.5.3.2. Surface topography and selective porosity -- 10.5.4. Chemical modification of material devices -- 10.5.4.1. Identification of anti-fibrotic chemistries: Surface vs. bulk modified -- 10.5.4.2. Zwitterionic (and other polymer-based) biocompatibility coatings -- 10.5.5. Long-term controlled release systems for rejection prevention -- 10.6. Pre/clinical observations, and models for translation -- 10.6.1. Choosing the right test animal and transplant site -- 10.6.2. Blood flow and nutrient considerations for graft viability -- 10.7. Future prospects and perceived challenges/difficulties -- 10.7.1. Increasing burdens on healthcare -- 10.7.2. Population expansion and increasing age of the general human populace -- 10.7.3. Increase in emerging diseases -- 10.8. Summary/conclusion -- References -- Chapter 11: Machine learning and mechanistic computational modeling of inflammation as tools for designing immuno -- 11.1. Biomaterials, inflammation, and wound healing.
,
11.2. Inflammation and wound healing as prototypical complex systems.
Additional Edition:
ISBN 0-12-821440-6
Language:
English